Compare WVE & EEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WVE | EEX |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | Singapore | United States |
| Employees | N/A | 821 |
| Industry | Biotechnology: Pharmaceutical Preparations | Advertising |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 890.6M |
| IPO Year | 2015 | N/A |
| Metric | WVE | EEX |
|---|---|---|
| Price | $6.27 | $5.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 1 |
| Target Price | ★ $29.81 | $7.70 |
| AVG Volume (30 Days) | ★ 3.3M | 83.0K |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 1.27% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,704,000.00 | N/A |
| Revenue This Year | N/A | $7.49 |
| Revenue Next Year | $85.67 | $6.81 |
| P/E Ratio | ★ N/A | $236.96 |
| Revenue Growth | ★ 149.43 | N/A |
| 52 Week Low | $5.02 | $3.32 |
| 52 Week High | $21.73 | $5.45 |
| Indicator | WVE | EEX |
|---|---|---|
| Relative Strength Index (RSI) | 53.10 | 55.31 |
| Support Level | $6.02 | $4.42 |
| Resistance Level | $6.31 | $5.08 |
| Average True Range (ATR) | 0.29 | 0.02 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 89.52 | 60.00 |
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Emerald Holding Inc is a business-to-business (B2B) event organizer principally in the United States, with operations in the United Kingdom (U.K.), France, and other markets. The company is engaged in three complementary business lines: Connections division consists of a collection of B2B trade show franchises and other live events that provide exhibitors opportunities to engage with buyers and expand their brand's awareness in their industry; the Content division consists of B2B print publications and digital media products that complement existing trade show properties, and the Commerce division provides B2B e-commerce and digital merchandising solutions to manufacturers and retailers. Emerald's key revenue is derived from the Connections business, its only reportable segment.